3K3A-APC demonstrates safety in clinical trial for acute ischemic stroke

A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug…


A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug. The trial results also show that 3K3A-APC substantially reduced haemorrhage volume and haemorrhage incidence in patients.

“These results lay the groundwork for the next steps toward FDA approval,” says Dr John Griffin, Professor at The Scripps Research Institute (TSRI), whose team invented 3K3A-APC.

Stroke is the fifth leading cause of death in the United States and the number one cause of adult disability. Acute ischemic strokes occur when a clot blocks blood flow to the brain. To date, the FDA has approved only one drug treatment, called tissue plasminogen activator (tPA), to treat acute ischemic strokes. tPA helps break up blood clots if given within a 4.5-hour window after the stroke.

Unfortunately, tPA’s use is limited due to this brief treatment window and its potential to cause bleeding in the brain and neuronal cell death. But studies so far show that 3K3A-APC could complement tPA administration. Dr Griffin designed the experimental drug by modifying just three amino acids on a naturally occurring blood protein called protein C, which is both an anticoagulant and a cell protective agent.

“This is an extremely novel drug,” says Dr Griffin.

Preclinical testing in collaborative studies involving Griffin’s lab and the lab of Dr Berislav Zlokovic, director of the Zilkha Neurogenetic Institute at the University of Southern California, showed that 3K3A-APC lessens the damage of stroke and protects brain cells from the side effects of tPA. The drug was licensed by TSRI to the pharmaceutical company ZZ Biotech, where Zlokovic was the scientific founder.

To find the maximally tolerated dose, the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS) funded the recent Phase 2 study, called RHAPSODY, through a grant to the principal investigator Dr Patrick Lyden, chair of the Department of Neurology at Cedars-Sinai in Los Angeles, and through a NeuroNEXT Infrastructure Resource Access grant to ZZ Biotech, where Dr Kent Pryor, served as co-principal investigator. NINDS entered into a Cooperative Research and Development Agreement (CRADA) with ZZ Biotech.

For the placebo-controlled dose-escalation trial, the researchers evaluated 3K3A-APC in patients with acute ischemic stroke treated with intravenous tPA, intra-arterial thrombectomy, or both. The scientists evaluated four doses of the drug: 120, 240, 360 and 540 μg/kg. Study participants, aged 18 to 90, were followed for 90 days. All doses were deemed safe and well tolerated.

As a secondary endpoint, the researchers evaluated cerebral haemorrhage in these patients. They found that total haemorrhage volume and haemorrhage incidence were both substantially reduced in 3K3A-APC-treated patients. The incidence of any haemorrhage was reduced from 86.5 percent in placebo-treated patients to 67.4 percent in the combined treatment arms. Total haemorrhage volume was likewise reduced from an average of 2.1±5.8 mL on placebo to 0.8±2.1 mL in the combined treatment arms.

The next steps for the researchers are to confirm and extend the successful Phase 2 study results in larger clinical trials.

Dr Griffin says the collaborative environment at TSRI made the development of 3K3A-APC possible. “I’ve been blessed by working with fantastic people. TSRI has been committed to basic research and discovery of new knowledge, especially with translational potential–and that’s been my philosophy.”

Send this to a friend